目的观察厄贝沙坦(安博维)联合美托洛尔(倍他乐克)治疗充血性心力衰竭(CHF)的临床效果。方法将68例充血性心力衰竭患者按随机数分配法分成两组。治疗组38例,除常规治疗外,口服厄贝沙坦和美托洛尔,美托洛尔小剂量开始,逐渐增量。对照组30例,给予常规抗心衰治疗。结果治疗组疗效优于对照组(u=3.564,P=0.000)。结论厄贝沙坦与美托洛尔联合应用治疗CHF简单易行,安全有效,对伴有心率增快和血压升高的CHF,更为适用。
ObjectiveTo observe the effect of irbesartan (Aprovel) and metoprolol (Betaloc) in the treatment of congestive heart failure (CHF) patients.Methods68 cases of CHF patients were randomly divided into two groups.38 cases of treatment group,in addition to conventional treatment, were given oral irbesartan and metoprolol,metoprolol dose to start small and gradually increase.30 cases of the control group were given conventional anti-heart failure treatment.ResultsThe efficacy of treatment group was significantly better than the control group (u=3.564, P=0.000).ConclusionIrbesartan in combination with metoprolol in the treatment of CHF is simple, safe and effective, and is more applicable for patients accompanied by rapid heart rate and blood pressure increase in CHF.